US-based Juno Therapeutics purchased a German biotech
Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich…
May 12, 2015 - 2 minutes
CAR-T Cell Therapy: Revolutionizing Oncology One Step at a Time
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
Show More
Editor's Picks for CAR-T
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?
- From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah
- Gene-Edited T Cell Therapy Players Battle Safety Doubts
- How European Startups Have Advanced Cancer T-Cell Therapy in 2020
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest CAR-T Articles
Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T
Just a week after announcing its intention to launch an IPO in the United States,…
April 8, 2015 - 2 minutes
Gene editing to make French fries less unhealthy
A promising biotechnological approach or an innovative way of avoiding regulation? Large companies spend an…
April 6, 2015 - 4 minutes
Merck Serono and Intrexon, to develop CAR-T Therapy
Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic…
March 31, 2015 - 2 minutes
With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever
Exactly one month ago, the article "Cellectis is preparing its IPO in the U.S" explained…
March 26, 2015 - 2 minutes
Review: The CRISPR’s Therapeutical revolution
Six years ago, a new sophisticated prokaryotic defense system, was identified in the structure complex…
January 21, 2015 - 4 minutes
